fear
thesi updat way sugarcoat quarter
guid worst case scenario term initi
impress core face perfect storm headwind
declin profit wise help
stoke fear aet transact defens maneuv
aim plug hole leaki bucket
clearli disappoint today print remain convinc
long term combin work creat valu
unfortun time frame thesi like
play notabl elong
manag must focu rebuild confid
base perpetu declin execut
sensibl challeng integr plan easi
reward pull materi move
needl healthcar cost allow improv profit
algorithm vertic integr entiti expect
focu june analyst day prove
hope posit catalyst share
model/pt updat forecast come materi
given numer headwind cover confer call
would note interest expens assumpt look
touch conserv could provid upsid ep later
forecast also move lower total
ebit growth return lsd year pt move
lower equat discount market
overal dcf impli modest growth
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
individu silverscript move pss hcb
aetna mail order specialti move pss
adjust oper incom exclud amort intang
season result echo
retail/ltc pbm yoy deterior highest adj op incom improv throughout year
hbc adj oper incom greatest lowest
annual tax reform invest half adj op incom contract
rx bn msd growth improv pharmaci program
medicar growth new region prefer relationship
front end margin dollar expect expand
reimburs cut off-set gener
omnicar tax reform invest half contract
work grow rx lower cost via autom red oak
work chang reimburs better reflect valu creat
biggest impact lower impact gener
price compress exacerb effect rebat guarante lower brand inflat
acceler timelin onboard revenu net basi
retent rate exclud transit pbm
rebat guarante impact peak roll
medicar growth medicaid win ks fl
strong commerci gain addit gov growth
make invest acceler growth
year synergi disproportion benefit hcb
suspens health insur fee impact certain oper ratio
develop new servic aid retail revenu
new product front end
new contract strategi better align valu provid reimburs
break open gener improv vs
transpar new contract
client receiv rebat
small number client adopt
expect
weigh new rebat rule believ number commerci solut would help
rebat guarante peak dissip
rebat within percentag point prior mm estim
get busi back track
benefit off-set snf issu
acceler plan see benefit
bn impair record
top-line new membership exist market plu geograph expans
expand offer higher acuiti complex member
medicaid build recent win kansa florida
new cost reduct plan addit mm synergi plan track exceed
new health servic offer avail sell season
valuat methodolog base mix discount cash flow analysi rel valuat multipl
potenti elev govern scrutini drug price transpar neg impact long-term profit gener via
potenti on-line competit amazon erod front end comp margin us pharmaci share
continu reimburs pressur us eu hit ultim lead total margin compress
laboratori corp america
articl articl
time dissemin februari
analyst elizabeth anderson ross muken michael newshel matthew nicolai primarili respons prepar research
report attest follow view opinion render research report reflect person view subject
compani issuer part research analyst compens directli relat specif
recommend view research report
